[Effect of blood derivatives with immunomodulators on the immunoprotein profile in calves under clinical conditions].
The data on the selected humoral and cellular parameters of the immuno-protein profile were evaluated in calves in a critical period of the availability of immunoglobulins (Ig), in dependence on the administration of the blood derivative with levamisole (group AL) and on the administration of levamisole solution (group L). The preparations were administered intramuscularly at a rate of 10 mg levamisole per 1 kg of live weight. No statistical significance was recorded in the comparison of the humoral parameters after repeated administration (interval of five days) of the Algalev (AL) and levamisole (L) preparations. During the same investigation, the administration of AL produced a significant increase in the T lymphocytes of the blood both in comparison with the T lymphocyte concentration before treatment (P less than 0.05 on the 5th, 7th, 11th, 14th and 20th day of experiment) and in comparison with the calves of group L (P less than 0.05 on the 7th, 11th, 14th, and 20th day); in the case of B lymphocytes an increase was recorded only in comparison with the initial value (P less than 0.01 on the 2nd, 5th and 7th day). Administration of levamisole alone led to a positive change in T lymphocyte concentration (P less than 0.05 on the 5th, 7th, 11th, 15th and 20th day) but not in the concentration of the B cells (P greater than 0.05). In another experiment, administration of the AL preparation (repeatedly after six days) led to a significant increase in the percentage of T lymphocytes (P less than 0.01 the 8th day and P less than 0.05 the 2nd, 6th, 15th, 21st and 35th day) and B lymphocytes (P less than 0.01 the 15th and 21st day), in comparison with their levels before administration as well as in comparison with the control (T lymph.: P less than 0.01 the 6th day and P les than 0.05 the 8th, 15th, 21st and 35th day; B lymph.: P less than 0.05 the 15th day). The maximum percent proportion of T lymphocytes after administration of the AL preparation was recorded on the seventh and eighth day after the first administration.
Paulík
S
S
Slanina
L
L
Dubaj
J
J
Borosková
Z
Z
Benková
M
M
Széchenyi
S
S
D000818:Animals; D002417:Cattle / Q000276:immunology*; D004338:Drug Combinations / Q000008:administration & dosage / Q000494:pharmacology; D007136:Immunoglobulins / Q000032:analysis*; D007958:Leukocyte Count / Q000187:drug effects; D007978:Levamisole / Q000008:administration & dosage* / Q000494:pharmacology; D008214:Lymphocytes / Q000187:drug effects*; D012710:Serum Albumin, Bovine / Q000008:administration & dosage* / Q000494:pharmacology; D005719:gamma-Globulins / Q000008:administration & dosage* / Q000494:pharmacology
C063553:Algalev; D004338:Drug Combinations; D007136:Immunoglobulins; D005719:gamma-Globulins; D012710:Serum Albumin, Bovine; D007978:Levamisole
Vplyv krvného derivátu s imunomodulátorom na imunobielkovinový profil u teliat v klinických podmienkach.